CalciMedica Files 8-K: Reg FD, Other Events, Exhibits

Ticker: CALC · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1534133

Calcimedica, INC. 8-K Filing Summary
FieldDetail
CompanyCalcimedica, INC. (CALC)
Form Type8-K
Filed DateJun 27, 2024
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

CalciMedica dropped an 8-K with Reg FD news and financials.

AI Summary

On June 27, 2024, CalciMedica, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes Financial Statements and Exhibits. The company, formerly known as Graybug Vision, Inc., is incorporated in Delaware and headquartered in La Jolla, California.

Why It Matters

This 8-K filing provides important updates and disclosures for CalciMedica, Inc., which could impact investor understanding of the company's current status and future outlook.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

FAQ

What specific event triggered the Regulation FD Disclosure?

The filing does not specify the exact event that triggered the Regulation FD Disclosure, only that it is included in the report.

What types of exhibits are included in this filing?

The filing indicates that Financial Statements and Exhibits are included, but does not list the specific exhibits.

When was CalciMedica, Inc. previously known as Graybug Vision, Inc.?

The company was formerly known as Graybug Vision, Inc. until a name change on March 22, 2023.

What is CalciMedica, Inc.'s Standard Industrial Classification code?

CalciMedica, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Where is CalciMedica, Inc. incorporated?

CalciMedica, Inc. is incorporated in Delaware.

Filing Stats: 1,868 words · 7 min read · ~6 pages · Grade level 11.4 · Accepted 2024-06-27 08:45:55

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release regarding Phase 2b CARPO Trial Topline Data, dated June 27, 2024. 99.2 Corporate Presentation of the Company, dated June 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 27, 2024 CalciMedica, Inc. By: /s/ A. Rachel Leheny, Ph.D. Name: A. Rachel Leheny, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing